Biochemical warfare tests; embryonic stem cell experiments; comparative effectiveness research
The deceptive marketing of antipsychotic drugs has prompted new advocacy group to launch "The Just Say "Know" to Prescription Drugs Campaign." Its goal is to get one million people to stop and reevaluate the medications they are taking.
"it’s an arms race between insurers, who deploy software and manpower trying to find claims they can reject, and doctors and hospitals, who deploy their own forces in an effort to outsmart or challenge the insurers.
http://hedwig.mgh.harvard.edu/ardsnet/faq.html#3 The individuals participating in the ARDS Network are listed below: Steering Committee Chair: Gordon Bernard, M.D., Vanderbilt University Clinical Coordinating Center: Massachusetts General Hospital: David Schoenfeld, Ph.D. B. Taylor Thompson, M.D. Nancy Ringwood, R.N., CCRA Cathryn Oldmixon, R.N. NHLBI Project Office: Andrea Harabin, Ph.D. Myron…
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post Thu, 18 Nov 2004 The Washington Post examines FDA’s record of surveillance and the evidence is clear: since 1992 when Congress required drug companies to pay users fees to the FDA, the agency’s focus changed from safety…
Antidepressant Makers Withhold Data on Children – Washington Post Thu, 29 Jan 2004 A front page article in The Washington Post addresses the key issue undermining public health and safety. Drug companies conceal unfavorable clinical trial findings: the tests failed to demonstrate that antidepressants are either safe or beneficial for…
More CDC Dirty Work re: ANTHRAX Vaccine – Meryl Nass, MD Wed, 20 Nov 2002 More indications that non-medical considerations are influencing the government’s anti-bioterrorism vaccine policy. In her column on RedFlags Weekly, Dr. Meryl Nass, board member of The Alliance for Human Research Protection, challenges the ethics of the…
July 08, 2002 Critique: U.S. to Vaccinate 500,000 Workers Against Smallpox 7 Jul 2002 FYI Dr. Meryl Nass, a member of the board of The Alliance for Human Research Protection and a recognized expert on Gulf War Syndrome and the use and consequences of experimental vaccines, raises serious concerns about…
OHRP Investigation of experimental treatment for Acute Respiratory Distress Syndrome. ARDSNet studies: ARMA, FACCT, and ALVEOLI Table of Contents to Fax from OHRP page 1 Oct. 7, 2002 OHRP letter to: Ronald S. Newvbower, Ph.D(Mass. General Hospital), Lee E. Limbird, Ph.D. (Vanderbilt University), and Robert Kay, MD) (Cleveland Clinic Foundation)…
AHRP Letter to Editor re: ARDS published NEJM Fri, 11 Jul 2003 A truncated version of a Letter to the editor submitted by John H. Noble, Jr., PhD and Vera Sharav appears in the current July 10, 2003, issue of The New England Journal of Medicine. Note: On April 3,…
Tomorrow Hearing FDA’s Emergency Research Rule–CNN News at 8:00 P.M will inform the public about how the FDA Rule impacts on American citizens who can be put at increased risk to test an experimental treatment without their knowledge or consent.
On June 10, 2003, a panel of experts convened by the federal Office of Human Research Protections (OHRP) heard presentations by critics who had filed complaints about $37 million government sponsored, multi-site experiment conducted by major academic institutions participating in the ARDSNetwork, and by the ARDSNet investigators who defend the trial.
The experiment tested two extreme, rarely used methods of mechanical lung ventilation in 861 critically ill, vulnerable patients suffering from acute lung disease (ALD) or acute respiratory distress syndrome (ARDS).
January 7, 2002 FYI MAD IN AMERICA (Perseus Press), a new book by Robert Whitaker, a prize winning science journalist, is sure to cause a stir. Whitaker holds psychiatry’s feet to the fire by examining the evidence in the professional psychiatric literature, FDA documents, published treatment outcome studies–including the World…
